Drug-resistant tuberculosis in Nepal: the sixth national prevalence drug-resistant survey, 2024
Abstract
BACKGROUND: Tuberculosis (TB) remains a major public health challenge in Nepal, characterized by increasing drug-resistant TB (DR-TB) and constrained surveillance capacity. The sixth national DR-TB prevalence survey was therefore implemented to address this gap. This study aimed to estimate the national prevalence of DR-TB and identify risk factors among new and previously treated pulmonary TB patients.
METHODS: A national cross-sectional survey was conducted from December 2022 to January 2024, enrolling bacteriologically confirmed pulmonary TB patients using stratified cluster sampling at 49 diagnostic centers. Phenotypic and genotypic drug sensitivity testing was performed on 1768 Mycobacterium tuberculosis-confirmed samples. Logistic regression analysis estimated DR-TB prevalence and its associated risk factors.
RESULTS: Rifampicin resistance was identified in 2.2% [95% confidence interval (CI) 1.4-3.6] of new TB patients and 10.1% (95% CI 5.1-19) of previously treated patients. In total, 9.4% exhibited resistance to at least one first-line drug, with isoniazid exhibiting the highest resistance rate. Within the rifampicin-resistant TB (RR-TB) group, resistance to moxifloxacin was more prevalent among newly diagnosed patients than previously treated patients at both critical concentrations (55.3% vs. 33.3% at 0.25 µg/ml; 34.2% vs. 11.1% at 1 µg/ml). Previous TB treatment emerged as the strongest predictor of rifampicin resistance [adjusted odds ratio (aOR) = 4.1, 95% CI…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.